Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKrm22 Plc Regulatory News (KRM)

Share Price Information for Krm22 Plc (KRM)

Share Price is delayed by 15 minutes
Get Live Data
32.50    0.00 (0.00%)
Bid:
32.00
Ask:
33.00
Spread: 1.00 (3.125%)
Market Cap: £19.28m
KRM Live PriceLast checked at - London Stock Exchange

Intraday Krm22 Plc Share Chart

Half Year Trading Update

18 Jul 2024 07:00

RNS Number : 8454W
KRM22 PLC
18 July 2024
 

KRM22 plc

("KRM22", the "Group" or the "Company")

Half Year Trading Update

 

KRM22 plc, (AIM: KRM) the technology and software investment company with a particular focus on risk management in capital markets, today issues the following trading update for the six months ended 30 June 2024 (the "Period") which is in line with management's expectations.

The Company has continued to make good progress in the Period increasing the value of its Annual Recurring Revenue ("ARR") from £5.4m at the end of FY 2023 to £6.0m at the end of the Period and, as at the date of this announcement, the Company's ARR has further increased to £6.1m.

The Company expects to report results for the Period in September 2024, and these are estimated to be:

· ARR: £6.0m (H1 2022: £5.0m)

· Total revenue: £3.3m (H1 2023: £2.4m)

· Adjusted EBITDA: £0.3m (H1 2023: loss of £1.0m)

· Cash balance as at 30 June 2024: £0.6m (FY 2023: £0.9m)

· Net debt at 30 June 2024: £3.9m (FY 2023: £3.6m)

 

A total of £1.1m of new ARR was generated in the Period through both sales to new customers, new product sales to existing customers and contractual price increases. Sales of the Limits Manager product has continued and KRM22 now has ARR contracts in place for its Limits Manager product with nine Futures Commission Merchants ("FCMs"), of which four have been signed in the Period, with two contracts through direct sales, one contract through the distribution agreement with Trading Technologies International, Inc. ("TT") and one additional contract which was originally entered into through the TT distribution agreement and subsequently transferred to KRM22. The Company did see customer churn of £0.4m in the Period, primarily from three customers for the Market Surveillance product, Post-Trade Stress product and one customer with multiple products who terminated their contract as they were closing their futures trading desk.

The Company has a strong pipeline of sales opportunities for the Limits Manager product. Risk Manager, which combines the legacy At-Trade and Post-Trade products, together with new functionality, is creating additional new sales opportunities with both new and existing customers.

As announced in the February 2024 trading update, the Company implemented a focused cost savings program with annual cost savings of approximately £1.2m. This decisive action, together with the increase in total revenue recognised in the Period compared with H1 2023 and the continued careful management of the underlying cost base of the business, has contributed to the Company reporting an adjusted EBITDA profit for the period of £0.3m. The Company has benefited from one-off non-recurring revenue being recognised in the Period meaning that management expectations for the full year outturn remain unchanged.

The Company's cash balance of £0.6m, together with the availability of £0.5m, which remains undrawn, under the TT convertible loan, means that the Company expects to continue to operate within its existing cash and debt facilities. However, the Board remains focused on careful cash management as it enters the second half of the year.

Dan Carter, CEO of KRM22, commented: "KRM22 has had strong first half of 2024 with ARR now at £6.1m and, with a substantial pipeline of sales opportunities through the remainder of the year and in to 2025, this growth is expected to continue as we drive towards our target of becoming a £10.0m ARR business."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

For further information please contact:

 

KRM22 plc InvestorRelations@krm22.com

Garry Jones, Non-Executive Chairman

Dan Carter, CEO

Kim Suter, CFO

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker) +44 (0)20 7220 0500

Carl Holmes / George Dollemore (Corporate Finance)

Sunila de Silva (ECM)

 

About KRM22 plc

KRM22 is a closed-ended investment company which listed on AIM on 30 April 2018. The Company has been established with the objective of creating value for its investors through the investment in, and subsequent growth and development of, target companies in the technology and software sector, with a focus on risk management in capital markets.

 

Through its investments and the Global Risk Platform, KRM22 helps capital market companies reduce the cost and complexity of risk management. The Global Risk Platform provides applications to help address firms' trading and corporate risk challenges and to manage their entire enterprise risk profile.

 

Capital markets companies' partner with KRM22 to optimise risk management systems and processes, improving profitability and expanding opportunities to increase portfolio returns by leveraging risk as alpha.

 

KRM22 plc is listed on AIM and the Group is headquartered in London, with offices in several of the world's major financial centres.

 

See more about KRM22 at www.krm22.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFMEFWELSEEW
Date   Source Headline
26th May 20263:24 pmRNSHolding(s) in Company
26th May 20262:25 pmRNSHolding(s) in Company
22nd May 20267:00 amRNSDirector Dealings
20th May 202611:19 amRNSDirector Dealings
20th May 20267:00 amRNSNotice of AGM and Posting of Annual Report
13th May 20267:00 amRNSFinal Results
29th Jan 20267:00 amRNSTrading Update
7th Jan 20267:00 amRNSAppointment of Director
20th Nov 20254:12 pmRNSTR-1
11th Nov 20257:00 amRNSIssue of Equity
10th Nov 20259:28 amRNSHolding(s) in Company
5th Nov 20251:05 pmRNSResult of GM
15th Oct 20257:00 amRNSResult of Placing
14th Oct 20254:50 pmRNSProposed Placing and Subscription
17th Sep 20257:00 amRNSInterim Results
7th Aug 20257:00 amRNSTrading Update
21st Jul 20257:00 amRNSIssue of Equity
27th Jun 20252:10 pmRNSResult of AGM
6th Jun 20257:00 amRNSDirector Dealing
2nd Jun 20257:00 amRNSIssue of Restricted Stock Units
30th May 20257:00 amRNSNotice of AGM and Posting of Annual Report
21st May 20257:00 amRNSDirector Dealing
19th May 20257:00 amRNSFinal Results
29th Apr 20257:00 amRNSFacility Amendment
7th Apr 20257:00 amRNSNew Customer Contracts
1st Apr 20257:00 amRNSFacility Amendment
18th Mar 20257:00 amRNSIssue of Equity
4th Mar 20257:00 amRNSNew Customer Contract
13th Feb 20255:00 pmRNSDirector Dealing
22nd Jan 20257:00 amRNSTrading Update
10th Jan 20257:00 amRNSIssue of Equity
23rd Dec 20247:00 amRNSLoan Facility Amendment
15th Oct 20247:00 amRNSIssue of Equity
25th Sep 20247:00 amRNSInterim Results
3rd Sep 20247:00 amRNSChange of Registered Office
29th Aug 20247:00 amRNSNew Customer Contract
22nd Aug 202410:00 amRNSGrant of Options and Director/PDMR Shareholding
19th Aug 20247:00 amRNSIssue of Equity
18th Jul 20247:00 amRNSHalf Year Trading Update
21st Jun 202412:49 pmRNSResult of AGM
29th May 20247:00 amRNSNotice of AGM and Posting of Annual Report
22nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSDirector Dealings
15th Apr 20247:00 amRNSNew Customer Contract
10th Apr 20247:00 amRNSIssue of Equity
7th Mar 20247:00 amRNSBoard Changes
21st Feb 20247:00 amRNSTrading Update
1st Dec 20237:00 amRNSIssue of Restricted Stock Units
26th Sep 20237:00 amRNSInterim Results
27th Jul 202311:48 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.